TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.75
−2.17%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.89
From 52W high−57.89%
Volume348950.00
Market cap$262.82M
P/E (TTM)—
P/S (TTM)56.1x
Div yield—
Key dataSep 18, 2026
Open
$6.89
From 52W high
−57.89%
Volume
348950.00
Market cap
$262.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
45.4
MomentumView details →
1D Return
−2.17%
YTD Return
−34.05%
SummaryUpdated Jun 1, 2026
Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company founded in 2016 and headquartered in Boston, Massachusetts. Originally incorporated as CycloPorters, Inc., the company changed its name to Entrada Therapeutics in October 2017 and went public in October 2021. Entrada focuses on developing innovative therapeutics for neuromuscular diseases using its proprietary endosomal escape vehicle (EEV) platform technology. The company represents an emerging player in the specialized field of intracellular drug delivery, targeting conditions where traditional therapies have struggled to achieve adequate cellular penetration.
Similar companies
Latest newsMore news →
Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, awarding two $50,000 grants to support projects addressing healthcare disparities in the Duchenne muscular dystrophy community.10d agoEntrada Therapeutics reported Q2 2026 financial results with revenue of $0.9 million, a net loss of $42.8 million, and diluted EPS of -$1.01, compared to revenue of $2.0 million and a net loss of $43.1 million in Q2 2025.47d ago